title: Authors' reply to Davis.
authors.affiliation: Latralis Ltd, Banbury, United Kingdom. Electronic address: rjandhyala@latralis.com.
authors.forename: Ravi
authors.initials: R
authors.lastname: Jandhyala
authors.affiliation: Strategen, Ltd., Basingstoke, Hampshire, United Kingdom.
authors.forename: John R
authors.initials: JR
authors.lastname: Fullarton
authors.affiliation: University of Leeds, Leeds, West Yorkshire, United Kingdom.
authors.forename: Michael I
authors.initials: MI
authors.lastname: Bennett
mesh_terms: D059390:Breakthrough Pain / Q000453:epidemiology* / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D009020:Morphine; D005283:Fentanyl